Related Experiment Video

Updated: Jul 27, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers

J Lindenfeld1, A D Robertson, B D Lowes

  • 1Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA. JoAnn.Lindenfeld@UCHSC.edu

Journal of the American College of Cardiology
|December 12, 2001
PubMed

Insights

Aspirin use was associated with a reduced improvement in left ventricular ejection fraction (LVEF) in patients with heart failure treated with carvedilol. This finding highlights a potential negative interaction between aspirin and beta-blockers in heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Aspirin (ASA) is known to blunt vasodilation from ACE inhibitors and beta-blockers.
  • Previous research suggests ASA may diminish the mortality benefits of ACE inhibitors in heart failure.
  • The interaction between ASA and beta-blockers on cardiac remodeling in heart failure remained uninvestigated.

Purpose of the Study:

  • To investigate the hypothesis that aspirin may alter the beneficial effects of beta-blockers on left ventricular ejection fraction (LVEF).
  • To evaluate the impact of aspirin on left ventricular remodeling in patients with chronic heart failure receiving carvedilol.

Main Methods:

  • Retrospective analysis of patients from the Multicenter Oral Carvedilol Heart failure Assessment (MOCHA) trial.
  • Multivariate analysis was employed to determine if aspirin independently influenced LVEF improvement.

Main Results:

  • Aspirin nonusers showed a greater LVEF improvement (9.5 EF units) compared to aspirin users (5.8 EF units) in the carvedilol group (p=0.02).
  • Aspirin's detrimental effect on LVEF improvement was dose-related and observed in both placebo and carvedilol groups.
  • Aspirin did not significantly impact heart rate or systolic blood pressure response.

Conclusions:

  • Aspirin significantly impacts LVEF changes in heart failure patients with systolic dysfunction treated with carvedilol.
  • The underlying mechanisms for this interaction require further investigation.
  • Understanding the molecular basis of reverse remodeling factors is crucial for heart failure management.
Abstract

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...